BofA analyst Jason Zemansky raised the firm’s price target on Insmed (INSM) to $96 from $92 and keeps a Buy rating on the shares. The firm’s positive thesis reflects a favorable view of the non-cystic fibrosis bronchiectasis opportunity ahead of the brensocatib PDUFA deadline of August 12, but it also argues that brensocatib’s optionality in inflammation and immunology “remains underappreciated as a source of long-term, sustained growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- United Therapeutics price target lowered to $314 from $328 at BofA
- Innovative Gene Therapy Approach Drives Buy Rating for Insmed in DMD Treatment
- Insmed assumed with an Overweight at Morgan Stanley
- Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating
- Insmed price target raised to $110 from $105 at UBS